Clinical Trials Browser

Phase 2 × Hydroxyurea × 90 days × Clear all

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07033598 2026-03-05

PROSPERA

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT06955169 2026-02-17

MOMENTUM-1

Phase 2 Recruiting

Meningioma